Is Context Therapeutics Inc. (CNTX) a Buy, Sell, or Hold?
NASDAQ : CNTX
Context Therapeutics Inc.
$0.6303 USD
$0.01 (1.19%)
- Volume
- 1.21M
- Average Volume
- 2.27M
- Market Capitalization
- $57.91M
- P/E Ratio
- -1.49
- Dividend Yield
- 0.00%
- Price Target
- $5.25
- Year High
- $3.62
- Year Low
- $0.55
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.96
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Martin A. Lehr |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CNTX |
| CUSIP | 21077P108 |
| CIK | 0001842952 |
| Web | https://www.contexttherapeutics.com |
| Phone | 267 225 7416 |
| Currency | USD |
| Employees | 15 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 8.96 |
| Quick Ratio | 8.96 |
| Cash Ratio | 8.34 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 0.00 |
| Cash Flow | -0.34 |
| Price / Cash Flow | -1.76 |
| Price / Book | 1.15 |
Price Target and Rating
| Average Stock Price Forecast | $5.25 |
| High Stock Price Forecast | $6.00 |
| Low Stock Price Forecast | $4.50 |
| Forecast Upside/Downside | -87.99% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 6 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.38 |
| Trailing P/E Ratio | -1.49 |
| PEG Ratio | 0.05 |
| P/E Growth | 0.05 |
| Net Income | -$36.12M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -59.95% |
| Return on Assets | -68.34% |
Financials Score
| AltmanZ Score | 0.64 |
| Piotroski Score | 2.00 |
| Working Capital | 51.98M |
| Total Assets | 58.86M |
| Ebit | -40.23M |
| Market Cap | 57.23M |
| Total Liabilities | 6.66M |
Poll Results
About Context Therapeutics Inc. (NASDAQ:CNTX) Stock
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. ...
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-10 16:05:00
PHILADELPHIA, July 10, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted a non-qualified stock option award to purchase 146,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context.
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
2026-07-06 16:07:00
PHILADELPHIA, July 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the Company was added to the small-cap Russell 2000® and the broad-market Russell 3000® Indexes, effective at the close of U.S. equity markets on June 26, 2026.
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study
2026-06-15 11:10:23
Context Therapeutics Inc. (NASDAQ:CNTX) on Monday released interim Phase 1 data for CTIM-76, its CLDN6 x CD3 T-cell engaging bispecific antibody, showing early signs of efficacy and a favorable safety profile in patients with advanced, late-line platinum-resistant ovarian cancer.
2026-06-15 06:30:00
29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer (“PROC”) who progressed on a median of 7 prior lines of therapy
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-06-09 16:10:00
PHILADELPHIA, June 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted a non-qualified stock option award to purchase 146,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context.
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
2026-05-27 07:30:00
PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its presentation at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 7:35 a.m. ET.
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
2026-05-18 06:45:00
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
2026-05-06 16:18:00
Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim data for ongoing CT-95 (MSLN x CD3) trial expected in September 2026 Phase 1 initiation for CT-202 (Nectin-4 x CD3) trial expected in third quarter of 2026 Cash and cash equivalents of $54.5 million as of March 31, 2026 expected to fund operations into mid-2027 PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for the first quarter ended March 31, 2026, and reported on recent and upcoming business highlights. “We continue to execute across our pipeline and believe we are making meaningful scientific and operational progress,” said Martin Lehr, Chief Executive Officer of Context Therapeutics.
Frequently Asked Questions
-
What is the current Context Therapeutics Inc. (CNTX) stock price?
-
Context Therapeutics Inc.(NASDAQ:CNTX) stock price is $0.6303 in the last trading session. During the trading session, CNTX stock reached the peak price of $3.62 while $0.545 was the lowest point it dropped to. The percentage change in CNTX stock occurred in the recent session was 1.19% while the dollar amount for the price change in CNTX stock was $0.01.
-
CNTX's industry and sector of operation?
-
The NASDAQ listed CNTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CNTX?
-
Martin A. Lehr | Co-Founder, President, Chief Executive Officer & Director
Jennifer Minai-Azary | Chief Financial Officer & Treasurer
Jennifer Dashnau | Senior Vice President of Technical Operations
Karen Chagin | Chief Medical Officer
Alex C. Levit | Chief Legal Officer & Corporate Secretary -
How many employees does CNTX have?
-
Number of CNTX employees currently stands at 15. CNTX operates from 2001 Market Street, Philadelphia, PA 19103, US.
-
Link for CNTX official website?
-
Official Website of CNTX is: https://www.contexttherapeutics.com
-
How do I contact CNTX?
-
CNTX could be contacted at phone #267 225 7416 and can also be accessed through its website. CNTX operates from 2001 Market Street, Philadelphia, PA 19103, US.
-
How many shares of CNTX are traded daily?
-
The average number of CNTX shares traded daily for last 3 months was 2.27M.
-
What is the market cap of CNTX currently?
-
The market value of CNTX currently stands at $57.91M with its latest stock price at $0.6303